(CIDRAP News) A federal advisory committee is recommending that 11 bacterial species and viruses on the current "select agent" list, including anthrax and Ebola virus, be singled out for special safeguards and that another 19 agents be dropped from the list entirely.
(CIDRAP News) Two biotechnology companiesCrucell, based in the Netherlands, and Integrated BioTherapeutics, based in Germantown, Md.recently announced that they have received $30 million and $22 million contracts, respectively, from the National Institutes of Allergy and Infectious Diseases (NIAID) to develop single vaccines that would protect against both Ebola and Marburg viruses.
(CIDRAP News) Soon after the terrorist attacks of 2001, Congress approved emergency funds to teach hospital staffs how to recognize and respond to bioterrorism attacks, and today the US Centers for Disease Control and Prevention (CDC) released its first report on those efforts.
(CIDRAP News) The National Institutes of Health (NIH) today announced the start of the first human trial of a vaccine for Ebola virus infection, a currently untreatable disease that kills most of its victims.
(CIDRAP News) Federal health officials yesterday released a 37-page report that they say demonstrates "tremendous progress" in developing countermeasures for bioterrorism through federally funded research since early 2002.
Editor's note: This story was updated Jan 30, 2003, with additional information from the Department of Health and Human Services.
(CIDRAP News) – President Bush yesterday proposed an initiative, called Project Bioshield, to speed the development and production of vaccines and treatments for smallpox, anthrax, botulism, and other diseases that could be spread by terrorists.
(CIDRAP News) The National Institute of Allergy and Infectious Diseases (NIAID) has released a 68-page report on its plan for expanding research on "Category A" bioterrorism agents: anthrax, smallpox, plague, tularemia, viral hemorrhagic fevers, and botulism.